个人简历

2009/07至今，山东大学，国家糖工程技术研究中心，任教 2004/09至2009/07，山东大学，药学院，博士研究生/博士 2000/09至2004/07，山东大学，药学院，本科/学士

研究领域

1、蛋白质化学修饰研究。 2、抗肿瘤药物研究。 3、糖类药物研究等。

近期论文

1. Zhendong Wang, Yan Li, Liang Xing, Feng Sun, Zhifang Yang, Fengshan Wang, and Haining Tan*. Effects of the anti-angiogenic carbohydrate-peptide conjugate, chitooligosaccharide-ES2 on endothelial cells and tumor-bearing mice. Carbohydrate Polymers, 208, 302-313, 2019. 2. Feng Sun, Zhendong Wang, Zhifang Yang, Yan Li, Huifei Cui, Chunhui Liu, DezongGao, Fengshan Wang, and Haining Tan*. Characterization, bioactivity and pharmacokinetic study of a novel carbohydrate-peptide polymer: glycol-split heparin-endostatin2 (GSHP-ES2). Carbohydrate Polymers, 207, 79-90, 2019. 3. Liang Xing, Feng Sun, Zhendong Wang, Yan Li, Zhifang Yang, Fengshan Wang, and Haining Tan*. Characterization and bioactivity of self-assembled anti-angiogenic chondroitin sulfate-ES2-AF nanoparticle conjugate. International Journal of Nanomedicine, 14, 2573–2589, 2019. 4. Feng Sun, Yang Yu, Zhifang Yang, Zhendong Wang, Yan Li, Fengshan Wang, and Haining Tan*. Hyaluronic acid-endostatin2-alft1 (HA-ES2-AF) nanoparticle-like conjugate for the target treatment of diseases. Journal of Controlled Release, 288,1-13, 2018. 5. Feng Sun, Abdul Sami Shaikh, Juan Wang, Hui Gao, Zhifang Yang, Zhendong Wang, Yan Li, Fengshan Wang, and Haining Tan*. Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin. Current Pharmaceutical Biotechonology, 19(12): 996 - 1004, 2018. 6. Yang Yu, Feng Sun, Congcong Zhang, Zhendong Wang, Jinfeng Liu, and Haining Tan*. Study on glyco-modification of endostatin-derived synthetic peptide endostatin2 (ES2) by soluble chitooligosaccharide. Carbohydrate Polymers, 154, 204-213, 2016. 7. Haining Tan, Shenglin Yang, Chunhui Liu, Jichao Cao, Guoying Mu, and Fengshan Wang*. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin. Biomedicine & Pharmcotherapy, 66(8),648-654,2012. 8. Haining Tan, Jichao Cao, Guoying Mu, Min Xiao and Fengshan Wang*. Preparation, characterization and anti-angiogenesis activity of endostatin covalently modified by polysulfated heparin. Pharmazie, 67(7),622-627,2012. 9. Haining Tan, Guoying Mu, Wei Zhu, Jinfeng Liu and Fengshan Wang*. Down-regulation of VEGF and up-regulation of PEDF make LMWH-endostatin and PEG-endostatin potential candidates for anti-angiogenesis drug. Biological Pharmceutical Bulletin, 34 (4), 545-50, 2011. 10. Juan Wang, Haining Tan (joint first author), Aihua Yu, Peixue Ling, Hongxiang Lou, Guangxi Zhai* and Jun Wu. Preparation of chitosan-based nanoparticles for delivery of low molecular weight heparin. Journal of Biomedical Nanotechnology, 7(5), 696-703,2011. 11. Haining Tan, Shenglin Yang, You Feng, Chunhui Liu, Jichao Cao, Guoying Mu and Fengshan Wang*. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin. Journal of Biochemistry, 144(2), 207–213,2008. 12. Huanli Xu, Haining Tan, Fengshan Wang*. Research advances of endostatin and its short internal fragments. Current protein and peptide science, 9,275-283, 2008.